An FDA advisory committee voted on Monday to recommend approval of dabigatran etexilate, an anticoagulant, to prevent strokes in patients with atrial fibrillation. In December, the New England Journal of Medicine published a study showing that dabigatran is as effective as warfarin in treating venous thromboembolism.
Tuesday, September 21, 2010
Possible Replacement for Coumadin (Warfarin)
Dabigatran Recommended by FDA Advisers
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment